We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Aggressive New HIV Strain Leads to AIDS Faster

By LabMedica International staff writers
Posted on 11 Dec 2013
A new aggressive strain of human immunodeficiency virus (HIV) develops more rapidly into acquired immunodeficiency syndrome (AIDS) than other current strains.

Human immunodeficiency virus type 1 (HIV-1) is characterized by a high genetic diversity, a consequence of an extremely high replication rate, an error-prone reverse transcriptase, recombination events during replication, and host selective immune pressure. More...
HIV-1 is divided into subtypes and the impact circulating recombinant forms (CRFs) need to be investigated.

Scientists at the Lund University (Sweden) analyzed blood samples obtained from individuals enrolled in a cohort comprising police officers in Guinea-Bissau. The cohort includes 225 HIV-1 seroincident individuals with estimated dates of seroconversion, defined as the midpoint between the last seronegative and the first seropositive sample. In total, samples were available for 191 individuals.

Viral ribonucleic acid (RNA) was extracted from blood plasma samples amplified by reverse-transcription polymerase chain reaction, and the C2–V3 region (460 bp) sequenced. Clones were amplified using Platinum Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA, USA) and conventional M13 primers (−20 and −24) and sequenced using primers JA170, JA169 or M13 reverse primer.

The major subtypes/CRFs identified were CRF02_AG (53%), A3 (29%), and A3/02 (a recombinant of A3 and CRF02_AG) (13%). Infection with A3/02 was associated with a close to three-fold increased risk of AIDS and AIDS-related death compared to A3, respectively. The estimated time from seroconversion to AIDS and AIDS-related death was 5 and 8 years for A3/02, 6 and 9 years for CRF02_AG, and 7 and 11 years for A3.

Patrik Medstrand, PhD, professor of Clinical Virology at Lund University, said, “HIV is an extremely dynamic and variable virus. New subtypes and recombinant forms of HIV-1 have been introduced to our part of the world, and it is highly likely that there are a large number of circulating recombinants of which we know little or nothing. We therefore need to be aware of how the HIV-1 epidemic changes over time.” The study was published in the November 2103 issue of the Journal of Infectious Diseases.

Related Links:

Lund University
Invitrogen 



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more

Molecular Diagnostics

view channel
Image: Researchers found that tumor DNA fragments in blood can reveal ongoing prostate cancer growth even when current tests show little change (image credit: Adobe Stock)

Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer

Prostate cancer is the most common cancer in the U.K., with more than 64,000 men diagnosed and 12,000 deaths each year. For the roughly 10,000 men annually with advanced disease, early assessment of treatment... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.